Close Menu

NEW YORK (GenomeWeb) – Cancer Genetics said today that New York State has approved the company's Focus::Myeloid next-generation sequencing-based panel for myeloid malignancies.

The 54-gene panel provides information that clinicians can use to diagnose, provide prognosis, determine treatment options, and provide risk stratification for patients with acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.